- Home
- KVUE vs TAK Comparison
KVUE vs TAK Comparison
Compare KVUE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KVUE
- TAK
- Stock Information
- Founded
- KVUE 2022
- TAK 1781
- Country
- KVUE United States
- TAK Japan
- Employees
- KVUE N/A
- TAK N/A
- Industry
- KVUE Specialty Chemicals
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- KVUE Consumer Discretionary
- TAK Health Care
- Exchange
- KVUE Nasdaq
- TAK Nasdaq
- Market Cap
- KVUE 43.6B
- TAK 42.2B
- IPO Year
- KVUE 2023
- TAK N/A
- Fundamental
- Price
- KVUE $23.88
- TAK $14.98
- Analyst Decision
- KVUE Buy
- TAK
- Analyst Count
- KVUE 14
- TAK 0
- Target Price
- KVUE $24.00
- TAK N/A
- AVG Volume (30 Days)
- KVUE 15.1M
- TAK 1.5M
- Earning Date
- KVUE 05-06-2025
- TAK 05-08-2025
- Dividend Yield
- KVUE 3.44%
- TAK 3.95%
- EPS Growth
- KVUE N/A
- TAK 15.39
- EPS
- KVUE 0.54
- TAK 0.83
- Revenue
- KVUE $15,455,000,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- KVUE $1.55
- TAK $8.53
- Revenue Next Year
- KVUE $4.12
- TAK N/A
- P/E Ratio
- KVUE $44.38
- TAK $34.51
- Revenue Growth
- KVUE 0.07
- TAK 9.83
- 52 Week Low
- KVUE $17.67
- TAK $12.58
- 52 Week High
- KVUE $24.46
- TAK $15.31
- Technical
- Relative Strength Index (RSI)
- KVUE 61.14
- TAK 57.24
- Support Level
- KVUE $22.80
- TAK $14.75
- Resistance Level
- KVUE $23.59
- TAK $15.17
- Average True Range (ATR)
- KVUE 0.46
- TAK 0.18
- MACD
- KVUE 0.00
- TAK -0.08
- Stochastic Oscillator
- KVUE 85.29
- TAK 40.18
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.